Clinical Trial Update: Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis [Phase 3]

View source ↗

Summary

A Phase 3 pediatric trial evaluating the efficacy and safety of drotrecogin alfa (activated) for severe sepsis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis

Drugs mentioned

• Drotrecogin alfa (activated) (drotrecogin alfa (activated))

Snippet

Sponsor: Eli Lilly and Company | Conditions: Sepsis | Phase 3 | Status: COMPLETED